EyebioKorea, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.eyebiokorea.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Phase 2
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- EyebioKorea, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06487039
- Locations
- 🇰🇷
Busan Paik Hospital, Inje University, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- EyebioKorea, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05538949
- Locations
- 🇰🇷
Busan Paik Hospital, Inje University, Busan, Korea, Republic of
News
No news found